Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 18, 1988 - Issue 2
29
Views
30
CrossRef citations to date
0
Altmetric
Original Article

Identification of metabolic pathways of pindolol and fluperlapine in adult human hepatocyte cultures

, , &
Pages 131-139 | Received 03 Feb 1987, Published online: 30 Sep 2009
 

Abstract

1. Adult human hepatocytes were obtained from a normal donor and a barbiturate-overdose fatality and maintained either in pure culture or in co-culture with rat liver epithelial cells. At varying times of culture, metabolic pathways of pindolol and fluperlapine, two drugs which are transformed at different rates and routes in man and rat, were determined after a 24 h incubation.

2. In both culture conditions, human hepatocytes remained able to form the major urinary metabolites of pindolol and fluperlapine, including oxidized products, glucuronide and sulphate conjugates over the whole period studied (i.e. 5 and 21 days in pure and co-culture respectively).

3. Fluperlapine which has the higher first pass in man and animals was found to be metabolized in vitro more quickly than pindolol.

4. Some qualitative and quantitative differences were found between normal and drug-altered human hepatocytes, indicating that in vivo environmental factors may greatly influence metabolic properties of these cells even after several days in culture.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.